AdvanCell

AdvanCell is a clinical-stage biopharmaceutical company pioneering the development of radioligand therapies (RLTs) that leverage the alpha-emitting isotope, Pb-212, for the treatment of cancer. AdvanCell is currently enrolling patients for the highest dose cohort of its multi-center TheraPb Ph I/II dose escalation clinical trial of ADVC001 for metastatic prostate cancer, a potentially best-in-class targeted alpha RLT. The trial aims to demonstrate the safety and efficacy of a Pb-212-based RLT.

Learn more at www.advancell.com.au